Nephros (NEPH) Competitors

Nephros (NASDAQ:NEPH) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Do insiders and institutionals believe in NEPH or LNSR?

41.1% of Nephros shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 38.5% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media favor NEPH or LNSR?

In the previous week, LENSAR had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat LENSAR's score of 1.87 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Very Positive
LENSAR	Very Positive

Which has preferable valuation and earnings, NEPH or LNSR?

Nephros has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$14.16M	2.67	$70K	$0.07	51.00
LENSAR	$53.49M	2.88	-$31.40M	-$4.85	-2.69

Do analysts rate NEPH or LNSR?

Nephros presently has a consensus price target of $5.00, indicating a potential upside of 40.06%. LENSAR has a consensus price target of $15.00, indicating a potential upside of 14.94%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts clearly believe Nephros is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
LENSAR	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk & volatility, NEPH or LNSR?

Nephros has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Is NEPH or LNSR more profitable?

Nephros has a net margin of 5.16% compared to LENSAR's net margin of -99.17%. Nephros' return on equity of 9.43% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	5.16%	9.43%	7.20%
LENSAR	-99.17%	-737.30%	-81.69%

Summary

Nephros beats LENSAR on 12 of the 16 factors compared between the two stocks.